Compare

Cerebrolysin vs SS-31

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Cerebrolysin

1329 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 63% · Mixed 20% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Lean mass
-136
Joint comfort
-119
Recovery
-72
Digestive comfort
-44
Skin appearance
-108

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Appetite loss
-40
Injection site reaction
-40
Anxiety
-107
Flushing
-48
Headache
-108

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.01–2 mg

0.01–0.025 mg
3
0.025–0.05 mg
11
0.05–0.1 mg
14
0.1–0.2 mg
19
0.2–0.4 mg
25
0.4–0.6 mg
17
0.6–1 mg
10
1–2 mg
7

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing13stacking11side effects29cerebrolysin12

How repeat users are trending

Among repeat reporters, 58% said they felt similar to their last entry, 31% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 29 days · Based on 292 repeat reporters

SS-31

603 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 57% · Mixed 32% · Unfavorable overall 11%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
2
Appetite control
-102
Energy
-3
Mood
-125
Focus
-141

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
-82
GI discomfort
-23
Dizziness
-38
Fatigue
-130
Nausea
-141

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.05 to ≥ 5 mg (open-ended top bucket)

0.05–0.1 mg
1
0.1–0.2 mg
5
0.2–0.4 mg
15
0.4–0.6 mg
19
0.6–1 mg
25
1–2 mg
22
2–3 mg
12
3–5 mg
4
5+ mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing47stacking10side effects23ss-3111

How repeat users are trending

Among repeat reporters, 52% said they felt similar to their last entry, 37% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 133 repeat reporters

Sources (8)

Published sources linked on the Cerebrolysin and SS-31 wiki pages.

  1. PubMed

    Cerebrolysin for acute ischemic stroke (review)

    Chen N, Yang M, Guo J, et al. Cochrane Database Syst Rev. 2017

    Source
    Wiki study page →
  2. PubMed

    Cerebrolysin for acute ischaemic stroke

    Ziganshina LE, Abakumova T, Nurkhametova D, et al. The Cochrane database of systematic reviews. 2023

    Source
    Wiki study page →
  3. PubMed

    Cerebrolysin for acute ischaemic stroke

    Ziganshina LE, Abakumova T, Vernay L. The Cochrane database of systematic reviews. 2017

    Source
    Wiki study page →
  4. PubMed

    Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane

    Szeto HH. AAPS J. 2006

    Source
    Wiki study page →
  5. PubMed

    Elamipretide in patients with heart failure with a reduced ejection fraction: EMBRACE-HF

    Butler J, Khan MS, Anker SD, et al. Eur J Heart Fail. 2020

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    Elamipretide (SS-31) studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. PubMed

    Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential

    Tung C, Varzideh F, Farroni E, et al. International journal of molecular sciences. 2025

    Source
    Wiki study page →
  8. PubMed

    Serendipity and the discovery of novel compounds that restore mitochondrial plasticity

    Szeto HH, Birk AV. Clinical pharmacology and therapeutics. 2014

    Source
    Wiki study page →